Seegene Inc Total Assets
Seegene Inc total assets. Based on the latest financial reports, Seegene Inc (096530) holds total assets worth ₩1.27 Trillion KRW (≈ $858.01 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Seegene Inc stock valuation for the company's overall valuation and market capitalisation.
Total Assets of Seegene Inc (2012–2025)
Total assets of Seegene Inc from 2012 to 2025. This chart illustrates how Seegene Inc's total assets have evolved over time, based on quarterly financial data. See Seegene Inc stock quote for real-time trading data and today's change.
Seegene Inc - Asset Composition Analysis
Seegene Inc Total Assets Breakdown (December 2025)
Seegene Inc total assets breakdown as of December 2025. Seegene Inc's total assets of ₩1.27 Trillion consist of 64.6% current assets and 35.4% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 18.3% |
| Accounts Receivable | ₩97.59 Billion | 7.9% |
| Inventory | ₩82.20 Billion | 6.7% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩19.60 Billion | 1.6% |
| Goodwill | ₩9.00 Billion | 0.7% |
Asset Composition Trend (2012–2025)
This chart illustrates how Seegene Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore 096530 current assets to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Seegene Inc's current assets represent 64.6% of total assets in 2025, an increase from 62.9% in 2012.
- Cash Position: Cash and equivalents constituted 18.3% of total assets in 2025, up from 5.2% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, an increase from 0.0% in 2012.
- Asset Diversification: The largest asset category is accounts receivable at 7.9% of total assets.
Seegene Inc Competitors by Total Assets
Key competitors of Seegene Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Seegene Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.62 | 4.71 | 3.47 |
| Quick Ratio | 4.19 | 4.12 | 2.51 |
| Cash Ratio | 0.00 | 0.00 | 1.48 |
| Working Capital | ₩642.03 Billion | ₩601.20 Billion | ₩643.03 Billion |
Seegene Inc - Advanced Valuation Insights
This section examines the relationship between Seegene Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.33 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 2.5% |
| Total Assets | ₩1.24 Trillion |
| Market Capitalization | $966.49 Million USD |
Valuation Analysis
Below Book Valuation: The market values Seegene Inc's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Seegene Inc's assets grew by 2.5% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Seegene Inc (2012–2025)
The table below shows the annual total assets of Seegene Inc from 2012 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ₩1.24 Trillion ≈ $837.48 Million |
+2.53% |
| 2024-12-31 | ₩1.21 Trillion ≈ $816.80 Million |
-3.69% |
| 2023-12-31 | ₩1.25 Trillion ≈ $848.09 Million |
-10.02% |
| 2022-12-31 | ₩1.39 Trillion ≈ $942.51 Million |
-6.64% |
| 2021-12-31 | ₩1.49 Trillion ≈ $1.01 Billion |
+36.10% |
| 2020-12-31 | ₩1.09 Trillion ≈ $741.78 Million |
+459.27% |
| 2019-12-31 | ₩195.72 Billion ≈ $132.63 Million |
+19.48% |
| 2018-12-31 | ₩163.81 Billion ≈ $111.01 Million |
-0.63% |
| 2017-12-31 | ₩164.84 Billion ≈ $111.71 Million |
-20.60% |
| 2016-12-31 | ₩207.62 Billion ≈ $140.70 Million |
+6.99% |
| 2015-12-31 | ₩194.05 Billion ≈ $131.50 Million |
+40.15% |
| 2014-12-31 | ₩138.45 Billion ≈ $93.83 Million |
+7.30% |
| 2013-12-31 | ₩129.04 Billion ≈ $87.45 Million |
+54.32% |
| 2012-12-31 | ₩83.62 Billion ≈ $56.67 Million |
-- |
About Seegene Inc
Seegene, Inc. manufactures and sells molecular diagnostics products worldwide. It offers IVD products comprising respiratory disease detection products for respiratory infections; gastrointestinal disease detection products for gastrointestinal tract infections; human papillomavirus detection products; sexually transmitted infections causative pathogens detection products; tuberculosis detection … Read more